Minodronic acid
Appearance
(Redirected from Minodronate)
![]() | |
Names | |
---|---|
Preferred IUPAC name
[1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diyl]bis(phosphonic acid) | |
Other names
Minodronate; YM 529
| |
Identifiers | |
| |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
PubChem CID
|
|
UNII |
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C9H12N2O7P2 | |
Molar mass | 322.150 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Minodronic acid is a third-generation bisphosphonate drug. It is approved for use in Japan for the treatment of osteoporosis.[1] Its mechanism of action involves inhibition of farnesyl pyrophosphate synthase activity.[2]
References
[edit]- ^ Shridhar Hegde and Michelle Schmidt (2009). "To Market, To Market - 2009. 16. Minodronic acid". Annual Reports in Medicinal Chemistry. 45: 509–510. doi:10.1016/s0065-7743(10)45028-9.
- ^ Sorbera, L.A.; Castañer, J.; Leeson, P.A. (2002). "Minodronic Acid". Drugs of the Future. 27 (10): 935–941. doi:10.1358/dof.2002.027.10.701186.